<DOC>
	<DOC>NCT01047683</DOC>
	<brief_summary>The primary objective is to determine the efficacy of AMR101 (ethyl icosapentate) compared to placebo in lowering fasting triglyceride levels in patients with very high fasting triglyceride levels ≥ 500 and ≤ 2000 mg/dL.</brief_summary>
	<brief_title>Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL</brief_title>
	<detailed_description />
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Eicosapentaenoic acid ethyl ester</mesh_term>
	<criteria>Men and women, ages &gt;18 Fasting triglyceride ≥500 mg/dL and ≤2000 mg/dL Provide written informed consent and authorization for protected health information disclosure Women who are pregnant or lactating, or planning to become pregnant Use of nonstatin lipidaltering drugs which cannot be stopped including fibrates, niacin, fish oil and other products containing omega3 fatty acids or other dietary supplements with potential lipidaltering effects History of pancreatitis History of bariatric surgery or currently on weight loss drugs Uncontrolled hypertension (BP &gt; 160/100) HIV infection or on treatment with HIVprotease inhibitors, cyclophosphamide,or isotretinoin Consumption of more than 2 alcoholic beverages per day History of cancers (except if been disease free for &gt;5 years OR history was basal or squamous cell skin cancer) Participation in another clinical trial involving an investigational agent in the last 30 days Other parameters will be assessed at the study center to ensure eligibility for this study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>hypertriglyceridemia</keyword>
	<keyword>omega-3 fatty acids</keyword>
	<keyword>statin</keyword>
	<keyword>triglycerides</keyword>
	<keyword>lipids</keyword>
	<keyword>EPA</keyword>
	<keyword>docosahexaenoic acid</keyword>
	<keyword>fish</keyword>
	<keyword>fatty acids</keyword>
	<keyword>fibrates</keyword>
	<keyword>niacin</keyword>
	<keyword>lipid</keyword>
	<keyword>atorvastatin</keyword>
	<keyword>Lovaza</keyword>
	<keyword>simvastatin</keyword>
	<keyword>lovastatin</keyword>
	<keyword>pravastatin</keyword>
	<keyword>fluvastatin</keyword>
	<keyword>rosuvastatin</keyword>
	<keyword>Trilipix</keyword>
	<keyword>Vytorin</keyword>
	<keyword>Simcor</keyword>
	<keyword>Niaspan</keyword>
	<keyword>ezetimibe</keyword>
	<keyword>Zetia</keyword>
	<keyword>ethyl-EPA</keyword>
	<keyword>ethyl icosapentate</keyword>
	<keyword>Crestor</keyword>
	<keyword>Zocor</keyword>
	<keyword>Lipitor</keyword>
	<keyword>LDL</keyword>
	<keyword>HDL</keyword>
	<keyword>cholesterol</keyword>
	<keyword>dyslipidemia</keyword>
	<keyword>VASCEPA</keyword>
	<keyword>icosapent ethyl</keyword>
</DOC>